How is semaglutide dose measured?
Semaglutide doses are measured in milligrams (mg) or micrograms (mcg). One milligram equals 1,000 micrograms. Published clinical trial doses range from 0.25 mg (250 mcg) during the initial titration phase up to 2.4 mg (2,400 mcg) at the weight management maintenance dose in the STEP 1 trial.
In a branded auto-injector pen, the prescribed dose is dialed in and the volume is delivered automatically. In a compounded semaglutide vial, the patient draws the appropriate volume from the vial using an insulin syringe. That is where “units” enter the picture.
Insulin syringes are calibrated in “units” (U-100 is the most common standard: 100 units per mL). In the context of semaglutide dosing, “units” is a syringe volume measurement, not a pharmacological potency unit like the international units (IU) used for insulin or growth hormone. The two uses of “units” are unrelated. Confusing them is a meaningful dosing risk.
How do you convert semaglutide mcg to units on a syringe?
The bridge between your prescribed dose in mcg and the number of units you draw is the concentration of your specific compounded preparation. Concentration is expressed as the amount of semaglutide (in mg or mcg) per unit volume (typically per mL).
Common compounded semaglutide concentrations include 2.5 mg/mL, 5 mg/mL, and 10 mg/mL, though concentrations vary by pharmacy and prescription. If your compound is 2.5 mg/mL and your prescribed dose is 0.25 mg, you draw 0.1 mL — which on a U-100 insulin syringe corresponds to 10 units.
| Prescribed dose | @ 2.5 mg/mL (U-100 units) | @ 5 mg/mL (U-100 units) | @ 10 mg/mL (U-100 units) |
|---|---|---|---|
| 0.25 mg (250 mcg) | 10 units | 5 units | 2.5 units |
| 0.5 mg (500 mcg) | 20 units | 10 units | 5 units |
| 1.0 mg (1,000 mcg) | 40 units | 20 units | 10 units |
| 1.7 mg (1,700 mcg) | 68 units | 34 units | 17 units |
| 2.4 mg (2,400 mcg) | 96 units | 48 units | 24 units |
Important: This table is for educational reference only. Always confirm the exact unit volume to draw with your prescribing clinician or compounding pharmacy before your first injection — vial concentrations vary by pharmacy and prescription.
Do not perform this conversion independently. Your prescribing clinician or compounding pharmacy will tell you exactly how many units to draw for your dose, based on the concentration of your specific vial. The math is not complicated, but an error in concentration (e.g., mistaking mg/mL for mcg/mL) produces a 1,000-fold dosing error. Always confirm the unit volume with your pharmacy before administering your first injection.
The same dose can be 10 units in one vial and 2.5 in another — concentration, not the dose itself, decides how many units you draw.
What is the standard semaglutide titration schedule?
GLP-1 receptor agonists are dosed on a gradual escalation schedule for a practical reason: the gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) that many patients experience are dose-dependent and reduce significantly when the dose is escalated slowly. Rushing titration is the most common reason patients experience unnecessary GI burden.
The titration schedule used in the STEP 1 trial (the largest published weight management trial for semaglutide) was structured as follows:
- Weeks 1–4: 0.25 mg (250 mcg) weekly — the starting dose, purely for tolerability, not expected to produce maximum effect.
- Weeks 5–8: 0.5 mg (500 mcg) weekly.
- Weeks 9–12: 1.0 mg (1,000 mcg) weekly.
- Weeks 13–16: 1.7 mg (1,700 mcg) weekly.
- Week 17 onward: 2.4 mg (2,400 mcg) weekly — the maintenance dose used in the trial.
Clinicians prescribing compounded semaglutide may use a similar escalation structure or adapt it based on individual patient response and tolerance. Some patients plateau at an intermediate dose and do not escalate to 2.4 mg — that is a clinical decision, not a protocol failure. Clinician review determines your specific schedule.
What affects how high a dose you’ll need?
Dose requirements are not uniform across patients. Factors that influence the dose at which a patient achieves meaningful response include:
- GI tolerability: The most common reason a dose is held at an intermediate level rather than escalated. Nausea, vomiting, or significant GI disruption at a given dose level typically means the clinician will pause escalation and reassess.
- Metabolic response: Some patients experience significant appetite suppression and satiety response at lower doses and do not require the maintenance dose to achieve their clinical goals.
- Body weight: Heavier patients may require higher doses to achieve comparable pharmacodynamic effects. This is not universal — individual sensitivity varies — but it is a factor clinicians consider.
- Concurrent medications: Some medications affect GI motility or interact with GLP-1 receptor agonist pathways. A complete medication review is part of the clinical intake.
Administration: subcutaneous injection, weekly cadence
Semaglutide for weight management is administered as a subcutaneous injection once weekly. Common injection sites include the abdomen (at least two inches from the navel), outer thigh, or upper arm. Sites should be rotated each week to avoid accumulation at a single site.
The injection is given with the same type of syringe used for insulin — a short, fine-gauge needle that makes the injection straightforward for most patients after the first few administrations. Your pharmacy and clinical team will review injection technique at the start of your protocol.
Day of week does not clinically matter for semaglutide’s pharmacokinetics — the half-life of approximately one week means the steady- state concentration is similar regardless of which day you inject. Consistency on the same day each week is a practical recommendation, not a pharmacological requirement.
Compounded semaglutide: sourcing and oversight
Compounded semaglutide is not the same product as branded injectable semaglutide. It is not FDA-approved. It is prepared by licensed 503A compounding pharmacies in the USA for individual patients with valid prescriptions, during periods of documented shortage.
At PepScribe, compounded semaglutide is prepared in the USA by licensed 503A pharmacies. No hidden overseas supply chain. Every prescription is issued by a licensed clinician after reviewing your intake. Ongoing check-ins are part of the program — not optional extras. The clinical oversight is what makes this a physician-supervised protocol rather than a mail-order supplement.
Frequently asked questions
What does "semaglutide dose in units" mean?
Semaglutide doses are primarily measured in micrograms (mcg or μg). In compounded semaglutide vials, the concentration is expressed as mcg per unit of volume (typically mcg per 0.1 mL or per mL), and patients draw the prescribed volume with an insulin syringe calibrated in units. "Units" in this context refers to syringe calibration markings, not international units (IU) as used in insulin dosing.
What is the standard starting dose for compounded semaglutide?
Clinicians typically prescribe a starting dose of 0.25 mg (250 mcg) weekly for the first 4 weeks to assess tolerability. The dose is then titrated upward based on clinical response and side-effect profile. The specific titration schedule is set by the prescribing clinician.
How do I convert semaglutide mcg to units on a syringe?
The conversion depends on the concentration of your specific compounded preparation. Your pharmacy will provide a concentration (e.g., 2.5 mg/mL or 5 mg/mL), and your clinician or pharmacy will tell you exactly how many units to draw for your prescribed dose. Never self-calculate unit volumes without that concentration information from your pharmacy.
What is the maximum semaglutide dose for weight management?
The maximum dose in published weight management trials (STEP 1) was 2.4 mg (2400 mcg) weekly. This is reached after a graduated titration schedule over approximately 16 weeks. Not all patients reach or should reach the maximum dose — clinicians individualize the dose based on response and tolerability.
Is semaglutide dosing the same for weight management and diabetes management?
No. The dose ranges and titration schedules differ between weight management and metabolic management indications. Weight management protocols in published trials reached 2.4 mg weekly; metabolic management doses in those same trials were lower. A clinician prescribes based on your specific goals and clinical context.